• Nuvectis Pharma held its annual shareholder meeting on June 11, 2026.
• Shareholders backed the appointment of Ron Bentsur as a Class I director, with the decision adopting the board outcome rather than confirming any subsequent actions.
• Investors ratified Kesselman & Kesselman as independent auditor for the fiscal year ending Dec. 31, 2026, with the vote confirming the selection rather than audit work performed.
• The company also corrected an earlier disclosure on the record-date share count, with no change to vote outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-073419), on June 12, 2026, and is solely responsible for the information contained therein.